Trials / Not Yet Recruiting
Not Yet RecruitingNCT06347458
BG1805 Injection in the Treatment of Relapsed or Refractory Acute Myeloid Leukemia in Children
A Single-arm, Dose-escalation and Dose-expansion Phase I Clinical Study to Evaluate the Tolerability, Safety and Preliminary Efficacy of BG1805 Injection in the Treatment of Relapsed or Refractory Acute Myeloid Leukemia in Children
- Status
- Not Yet Recruiting
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 24 (estimated)
- Sponsor
- Guangzhou Bio-gene Technology Co., Ltd · Industry
- Sex
- All
- Age
- 3 Years – 18 Years
- Healthy volunteers
- Not accepted
Summary
This is a single-arm, single-dose dose-escalation and dose-expansion study.
Detailed description
Child patients with relapsed/refractory acute myeloid leukemia (r/r AML) were enrolled in the trial, which was divided into two parts: dose-escalation phase and dose-expansion phase.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | BG1805 | A single infusion of BG1805 Injection administered intravenously. |
Timeline
- Start date
- 2024-04-01
- Primary completion
- 2027-04-01
- Completion
- 2027-08-01
- First posted
- 2024-04-04
- Last updated
- 2024-04-04
Source: ClinicalTrials.gov record NCT06347458. Inclusion in this directory is not an endorsement.